Amplyx Pharmaceuticals, Inc

@AmplyxPharma

Developing antifungal agents for the treatment of life-threatening invasive fungal infections due to Candida, Aspergillus and rare molds.

San Diego, CA
Vrijeme pridruživanja: svibanj 2019.

Tweetovi

Blokirali ste korisnika/cu @AmplyxPharma

Jeste li sigurni da želite vidjeti te tweetove? Time nećete deblokirati korisnika/cu @AmplyxPharma

  1. proslijedio/la je Tweet
    31. sij

    The Benchmark Report shows that, despite some progress, R&D has not increased enough to radically impact the problem of AMR. New legislation and regulations are needed to address the broken market and spur new life saving development

    Poništi
  2. proslijedio/la je Tweet
    29. sij

    Immediate action is needed to help the companies working to fight . Learn how legislation like the can help stabilize the antimicrobial market and spur the development of life-saving treatments:

    Poništi
  3. proslijedio/la je Tweet
    23. sij

    is evolving faster than new development. It is critical that policy makers fix the broken market. Learn more about the rising threat of and how legislation like the that has potential to help

    Poništi
  4. Poništi
  5. Poništi
  6. proslijedio/la je Tweet
    18. sij

    “We still have a window of opportunity but we need to ensure there is investment now so we don’t run out of options for future generations.”

    Poništi
  7. proslijedio/la je Tweet
    16. sij
    Poništi
  8. proslijedio/la je Tweet
    17. sij

    Without new action, the threat of will only grow. shares 5 priorities to combat AMR in 2020, including the use of economic incentives and passing the to catalyze the development of new life-saving :

    Poništi
  9. proslijedio/la je Tweet

    Lord Jim O'Neill calls for death certificates to include '' as cause of death in an effort to raise awareness of the crisis and improve the data scientists have to work with. via

    Poništi
  10. proslijedio/la je Tweet

    Almost 3 million resistant infections occur each year in the U.S. ' details the immense threat poses & ongoing efforts such as the DISARM Act to fix the broken market & spur antimicrobial development:

    Poništi
  11. Poništi
  12. Dr. Karen Shaw will present "Fighting Infections with Fosmanogepix: A first-in-class Antifungal Agent" at the CHARM UC San Diego meeting tomorrow from 4-7pm. Hope to see you there!

    Poništi
  13. proslijedio/la je Tweet
    18. stu 2019.

    IDSA’s Faces of Antimicrobial Resistance report highlights patients & their families who have suffered the debilitating effects of infections. These heart-wrenching stories demonstrate the urgent need to combat .

    Poništi
  14. Drug-Resistant Candida auris is now recognized as an URGENT Threat by the CDC, with an increasing number of strains resistant to all available therapies. New classes of antifungal therapies are needed!

    Poništi
  15. proslijedio/la je Tweet

    In order to spur action necessary to support innovation, we must continue to effectively communicate how drug-resistance undermines and can affect everyone. Learn how from :

    Poništi
  16. proslijedio/la je Tweet

    . President & CEO highlights the urgent need for new policies like the that will spur the development of novel to fight in his Op-Ed.

    Poništi
  17. A future without new antimicrobial therapies to address infections caused by resistant pathogens is truly SCARY! At Amplyx, we are proud to be developing innovative therapies for patients at risk for these often life-threatening infections.

    Poništi
  18. proslijedio/la je Tweet
    26. lis 2019.

    .: "antifungal resistance is rising and if you aren't testing, you don't know."

    Prikaži ovu nit
    Poništi
  19. proslijedio/la je Tweet
    26. lis 2019.

    .: "antifungal resistance is likely underappreciated since many institution do not routinely test Candida species susceptibilities" C. auris concerning due to multi-drug resistance + it is extremely hard to eradicate.

    Prikaži ovu nit
    Poništi
  20. We are proud to be a part of the 3X5 family! Sustainability, Life Sciences Investor 3x5 Doubles Team Amid Fundraising

    Poništi

Čini se da učitavanje traje već neko vrijeme.

Twitter je možda preopterećen ili ima kratkotrajnih poteškoća u radu. Pokušajte ponovno ili potražite dodatne informacije u odjeljku Status Twittera.

    Možda bi vam se svidjelo i ovo:

    ·